News | January 25, 2025
Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr
Q3 FY25 revenue up 24% to Rs 3,230 crore
Q3 FY25 revenue up 24% to Rs 3,230 crore
Expansion makes Merck Life Science in Bengaluru a key manufacturing location in the APAC region
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
PAT after MI is Rs. 41 crore which is 162% increase
EBITDA margins expand to 31.3%
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Subscribe To Our Newsletter & Stay Updated
